Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Ndumele highlighted the surprise in SOUL's lack of impact on cardiovascular mortality, which had been suggested in the FLOW trial on injectable semaglutide in people with more severe CKD.

SOUL vs FLOW Speaking to the difference in outcomes between FLOW, a study where semaglutide cut both cardiovascular risk and the progression of kidney disease, and SOUL, where there was no effect on ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Oral semaglutide reduced risk for cardiovascular ... as opposed to participants from the FLOW trial, which enrolled fewer patients who also had worse renal function and a much lower eGFR.

Oral semaglutide reduced major cardiovascular events by 14% in patients with type 2 diabetes over nearly 4 years. The trial involved 9650 patients with type 2 diabetes and cardiovascular or kidney ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...